CM
DSGN icon

Caption Management’s Design Therapeutics DSGN Stock Holding History

Caption Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$923K Buy
+86,708
New +$877K 0.01% 1046

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caption Management's DSGN Position: Q1 2026 in Review

Caption Management opened a new position in Design Therapeutics (DSGN) in Q1 2026: 86,708 shares worth $923K. The stake represents 0.01% of the portfolio and ranks #1046 among its holdings.

125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Caption Management held 86,708 shares of Design Therapeutics worth $923K as of Q1 2026.
  • Design Therapeutics was a new Caption Management position in Q1 2026.
  • Design Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #1046 holding.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.